Advances in the staging and treatment of ovarian cancer
- 1 February 1977
- Vol. 39 (S2), 967-972
- https://doi.org/10.1002/1097-0142(197702)39:2+<967::aid-cncr2820390736>3.0.co;2-g
Abstract
The age adjusted death rate for ovarian cancer has remained unchanged for the past 20 years. Recent data obtained by staging ovarian cancer patients with lymphangiography and peritoneoscopy demonstrated that many patients with apparently localized disease actually have occult dissemination within the abdomen. These new staging techniques plus the determination of the histologic grade of anaplasia may permit a more precise determination of a patient's prognosis and therefore better design of therapeutic stategy. Radiotherapeutic techniques are being adapted to attempt to treat some areas of occult disease. Numerous single chemotherapeutic agents are capable of producing objective tumor responses. Preliminary data suggest that combination chemotherapy can increase the objective response rate above that seen with single agents. Longer follow-up is necessary to determine whether combination chemotherapy can prolong survival.This publication has 14 references indexed in Scilit:
- The rationale for curative radiotherapy for ovarian carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1975
- Results of Postoperative Megavoltage Radiotherapy of Malignant Surface Epithelial Tumors of the OvaryRadiology, 1975
- LYMPHANGIOGRAPHY IN OVARIAN CANCERAmerican Journal of Roentgenology, 1975
- The chemotherapy of ovarian carcinomaCancer Treatment Reviews, 1974
- IRRADIATION OF OVARIAN CARCINOMASAmerican Journal of Roentgenology, 1974
- Lymphangiography in Prostatic CarcinomaPublished by American Medical Association (AMA) ,1973
- Treatment of Ovarian Carcinoma: Possibilities for ProgressNew England Journal of Medicine, 1972
- INTEGRATED THERAPY FOR EWING'S SARCOMAAmerican Journal of Roentgenology, 1972
- Observations on gynecologic malignancy treated with 5-fluorouracilAmerican Journal of Obstetrics and Gynecology, 1968
- Five Years Clinical Experience with 5-FluorouracilJAMA, 1962